Yun MR - Search Results

1

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.

Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ, Drilon A, Kang SG, Shim HS, Hong MH, Cui JJ, Kim HR, Cho BC. Yun MR, et al. Clin Cancer Res. 2020 Jul 1;26(13):3287-3295. doi: 10.1158/1078-0432.CCR-19-2777. Epub 2020 Apr 8. Clin Cancer Res. 2020. PMID: 32269053 Free PMC article.

2

Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation.

Kim SM, Yun MR, Hong YK, Solca F, Kim JH, Kim HJ, Cho BC. Kim SM, et al. Among authors: yun mr. Mol Cancer Ther. 2013 Oct;12(10):2145-56. doi: 10.1158/1535-7163.MCT-12-1188. Epub 2013 Jul 24. Mol Cancer Ther. 2013. PMID: 23883584

3

Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Kim HS, et al. Among authors: yun hj, yun mr. Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25. Clin Cancer Res. 2015. PMID: 25424851 Clinical Trial.

4

Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma.

Kang CW, Jang KW, Sohn J, Kim SM, Pyo KH, Kim H, Yun MR, Kang HN, Kim HR, Lim SM, Moon YW, Paik S, Kim DJ, Kim JH, Cho BC. Kang CW, et al. Among authors: yun mr. Mol Cancer Ther. 2015 Oct;14(10):2238-48. doi: 10.1158/1535-7163.MCT-15-0350. Epub 2015 Jul 24. Mol Cancer Ther. 2015. PMID: 26208525

5

ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.

Kang HN, Kim SH, Yun MR, Kim HR, Lim SM, Kim MS, Hong KW, Kim SM, Kim H, Pyo KH, Park HJ, Han JY, Youn HA, Chang KH, Cho BC. Kang HN, et al. Among authors: yun mr. Lung Cancer. 2016 May;95:57-64. doi: 10.1016/j.lungcan.2016.02.013. Epub 2016 Feb 27. Lung Cancer. 2016. PMID: 27040853

6

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.

Kim SM, Kim H, Jang KW, Kim MH, Sohn J, Yun MR, Kang HN, Kang CW, Kim HR, Lim SM, Moon YW, Kim JH, Paik S, Cho BC. Kim SM, et al. Among authors: yun mr. Mol Cancer Ther. 2016 Jul;15(7):1627-36. doi: 10.1158/1535-7163.MCT-15-0375. Epub 2016 May 11. Mol Cancer Ther. 2016. PMID: 27196768 Retracted.

7

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.

Kim SM, Kim H, Yun MR, Kang HN, Pyo KH, Park HJ, Lee JM, Choi HM, Ellinghaus P, Ocker M, Paik S, Kim HR, Cho BC. Kim SM, et al. Among authors: yun mr. Oncogenesis. 2016 Jul 18;5(7):e241. doi: 10.1038/oncsis.2016.48. Oncogenesis. 2016. PMID: 27429073 Free PMC article.

8

Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.

Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim SM, Kim H, Kang HN, Lee JM, Kim SG, Park CW, Chang H, Shim HS, Lee HW, Cho BC. Pyo KH, et al. Among authors: yun mr. J Thorac Oncol. 2017 Mar;12(3):491-500. doi: 10.1016/j.jtho.2016.10.022. Epub 2016 Nov 9. J Thorac Oncol. 2017. PMID: 27836576 Free article.

9

Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.

Kim HS, Jung M, Kang HN, Kim H, Park CW, Kim SM, Shin SJ, Kim SH, Kim SG, Kim EK, Yun MR, Zheng Z, Chung KY, Greenbowe J, Ali SM, Kim TM, Cho BC. Kim HS, et al. Among authors: yun mr. Oncogene. 2017 Jun 8;36(23):3334-3345. doi: 10.1038/onc.2016.486. Epub 2017 Jan 16. Oncogene. 2017. PMID: 28092667

10

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.

Kim HR, Kang HN, Shim HS, Kim EY, Kim J, Kim DJ, Lee JG, Lee CY, Hong MH, Kim SM, Kim H, Pyo KH, Yun MR, Park HJ, Han JY, Youn HA, Ahn MJ, Paik S, Kim TM, Cho BC. Kim HR, et al. Among authors: yun mr. Ann Oncol. 2017 Jun 1;28(6):1250-1259. doi: 10.1093/annonc/mdx098. Ann Oncol. 2017. PMID: 28460066 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page